Yingwei Wang, Xin Chen, Yafei Chen

Clinical laboratory,Tiantai people’s hospital, Tiantai, Zhejiang 317200, China.

Abstract

Background: The aim of the present study was to determine whether the interleukin-6 (IL-6) -572G/C polymorphism correlates with prostate cancer.

Methods: According to inclusion and exclusion criteria, the association of the IL-6 -572G/C polymorphism with prostate cancer was searched in databases and analyzed using comprehensive meta-analysis software. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the associations.

Results: We considered a total of six case-control studies including  2237 patients and 1754 controls and the meta-analysis results showed significant association between the IL-6 -572G/C polymorphism and prostate cancer risk(CC vs GG: OR = 0.49, 95% CI =0.37-0.65;CG vs GG: OR =0.71, 95% CI = 0.58-0.87; the dominant model: OR =0.65, 95% CI = 0.54-0.79;the recessive model: OR =0.70, 95% CI = 0.58-0.85). In stratified analyses by ethnicity, significant associations were found among Asian populations. However, no significant association was found in Caucasian populations.

Conclusion: Our findings demonstrated that the -572G/C polymorphism of the IL-6 gene may be a risk factor for the development of prostate cancer in Asians.

Keywords: Prostate cancer,IL-6 polymorphisms, risk. DOI: https://dx.doi.org/10.4314/ahs.v18i2.10

Cite as: Wang Y, Chen X, Chen Y. Interleukin-6 gene -572G/C polymorphism and prostate cancer risk. Afri Health Sci. 2018;18(2): 267-272. https://dx.doi.org/10.4314/ahs.v18i2.10

 Interleukin-6 gene -572GC polymorphism and prostate cancer risk.PDF.